WO2004032629A1 - 寄生虫防除用混合組成物 - Google Patents
寄生虫防除用混合組成物 Download PDFInfo
- Publication number
- WO2004032629A1 WO2004032629A1 PCT/JP2003/012003 JP0312003W WO2004032629A1 WO 2004032629 A1 WO2004032629 A1 WO 2004032629A1 JP 0312003 W JP0312003 W JP 0312003W WO 2004032629 A1 WO2004032629 A1 WO 2004032629A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- substituted
- halogen atom
- atom
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
- A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N53/00—Biocides, pest repellants or attractants, or plant growth regulators containing cyclopropane carboxylic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a mixed composition for controlling ectoparasites, comprising a halogen-substituted quinoline derivative and a pyrethroid insecticide, for controlling pests infesting mammals and birds.
- Japanese Patent No. 263333377 discloses a quinoline derivative as an insecticide for agricultural and horticultural use.
- pyrethroid insecticides have ectoparasite control activity is described in, for example, Pesticide Manuyanore (The Pesticide Manual, 12th edition, published by The British Crop Protection Council, 2000). Have been.
- the use of these pyrethroid insecticides over the years has resulted in some ectoparasites gaining drug resistance, making it very difficult to control these pests. Therefore, development of a drug that can control such drug-resistant pests is desired.
- ectoparasites that infest mammals and birds can cause symptoms such as malnutrition, weakness, weight loss, and reduced egg production by feeding the host animal.
- Many control agents have been developed for such ectoparasites, but there is a need for an immediate and safe drug that can reduce stress on host animals more quickly.
- the present inventors have now proposed a mixed composition comprising a quinoline derivative having a halogen substituent at a specific position of 4-acyloxyquinoline and at least one compound of a pyrethroid insecticide.
- a mixed composition comprising a quinoline derivative having a halogen substituent at a specific position of 4-acyloxyquinoline and at least one compound of a pyrethroid insecticide.
- they exhibit a significant synergistic effect compared to when each is used alone, and have excellent control effects on ectoparasites of mammals and birds.
- the present invention is based on such findings.
- an object of the present invention is to provide an agent for controlling ectoparasites of mammals and birds which has a high controlling effect on resistant pests, and which is immediate and safe.
- the mixed composition for controlling ectoparasites of mammals and birds comprises (a) a compound of the following formula (I) or a salt thereof, and (b) at least one kind selected from pyrethroid insecticides. And a compound as an active ingredient:
- a C 1-6 phenol group which may be substituted by a halogen atom or a cyano group
- a C 2-6 phenol group which may be substituted by a halogen atom or a cyano group
- a C 2-6 phenol which may be substituted by a halogen atom or a cyano group
- R 5 is an alkyl group having 1 to 6 carbon atoms which may be substituted by a halogen atom or a cyano group; 2 carbon atoms which may be substituted by a halogen atom or a cyano group
- An alkenyl group having from 6 to 6 represents an alkynyl group having 2 to 6 carbon atoms which may be substituted by a halogen atom or a cyano group
- R 2 represents an alkyl group having 1 to 4 carbon atoms which may be substituted by a halogen atom
- R 3 and R 4 represents a hydrogen atom, the other represents a fluorine atom, a chlorine atom, a bromine atom or a trifluoromethyl (1-CF 3 ) group;
- X represents a fluorine atom or a chlorine atom].
- the method for controlling ectoparasites of mammals and birds according to the present invention comprises a step of administering an effective amount of the mixed composition for controlling ectoparasites according to the present invention to target mammals and birds.
- the mixed composition for controlling ectoparasites of mammals and birds according to the present invention comprises, as described above, a compound of the formula (I) or a salt thereof, and at least one compound selected from pyrethroid insecticides. And as an active ingredient.
- halogen atom means a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom, and is preferably a fluorine atom or a chlorine atom.
- alkyl group means a straight-chain alkyl group, a branched alkyl group, or a cyclo (cyclic) alkyl group.
- alkyl group examples include linear alkyl groups such as a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, and a hexyl group; an isopropyl group, an isobutyl group, an S-butyl group, a t-butyl group, Branched alkyl groups such as neopentyl, isopentyl, and isohexyl
- cycloalkyl groups such as a cyclopropyl group, a 1-methylcyclopropyl group, a cyclopropylmethinole group, a cycloptynole group, a cyclopentyl group, and a cyclohexyl group.
- alkenyl group means a straight-chain alkenyl group, a branched alkenyl group, or a cycloalkenyl group.
- alkenyl group examples include a vinyl group, an aryl group, a propyl group, an isopropyl group, a butenyl group, a 2-butenyl group, a 3-buteninole group, a 2-methylolyl 1-probeyl group, a 2-methylaryl group.
- Penthen Nore group 2-penteninole group, 3-penteninole group, 4-penteninole group, cyclopenteninole group, hexeninole group, 2—hexeninole group, 3—hexeninole group, 4-hexeninole group , 5-hexenyl group, and cyclohexenyl group.
- alkynyl group means a straight-chain alkynyl group, a branched alkynyl group, or a cycloalkynyl group.
- Alkynyl groups include ethynyl, propyninole, 2-propyninole, butyninole, 2-butyninole, 3-pentinole, pentynyl, 2-pentulle, 3-pentulle, 4-pentulle, Xininole group, 2-hexininole group, 3_hexyl group, 4-hexininole group, and 5-hexyninyl group.
- the alkyl group having 1 to 6 carbon atoms can preferably be an alkyl group having 1 to 4 carbon atoms.
- the alkenyl group having 2 to 6 carbon atoms can preferably be an alkenyl group having 2 to 4 carbon atoms.
- the alkynyl group having 2 to 6 carbon atoms can preferably be an alkynyl group having 2 to 4 carbon atoms.
- preferred examples of the compound of the formula (I) include a compound of the formula (I) in which one of R 3 and R 4 represents a hydrogen atom and the other represents a fluorine atom or a chlorine atom. .
- the compound of formula (I) can be a compound of formula (Ia):
- R 11 represents an alkyl group having 1 to 4 carbon atoms which may be substituted by a halogen atom, or an alkoxy group having 1 to 4 carbon atoms which may be substituted by a halogen atom
- R 12 represents an alkyl group having 1 to 4 carbon atoms which may be substituted by a halogen atom;
- R 13 and R 14 represents a hydrogen atom, and the other represents a fluorine atom or a chlorine atom.
- Preferred examples of the compound of the formula (I) used in the present invention include compounds 1 to 81 described in Examples.
- compounds of formula (I) include compounds selected from the group consisting of:
- the compounds of formula (I) can form salts, for example, hydrochlorides, nitrates, phosphates, and acetates.
- the compound of the formula (I) can be synthesized by reacting the compound of the formula (II) with the reagent of the formula (III) without a solvent or using an appropriate solvent.
- a suitable base for example, an organic amine such as triethylamine or pyridine
- the compound of formula (I) can be synthesized by carrying out the reaction in the presence of an inorganic catalyst such as sodium carbonate, sodium carbonate, lithium carbonate or sodium hydride.
- a suitable condensing agent for example, dicyclohexylcarpoimide (DCC), 1-hydroxybenzotriazole (H ⁇ Bt), 2-chloro-1,3-dimethyl
- DCC dicyclohexylcarpoimide
- H ⁇ Bt 1-hydroxybenzotriazole
- 2-chloro-1,3-dimethyl The compound of formula (I) can be synthesized by carrying out the reaction in the presence of imimidazolinium chloride (DMC).
- the reagent of the formula (III) in an amount of 1 to 50 equivalents, preferably 1 to 10 equivalents, based on the compound of the formula (II).
- the solvent used is an organic solvent not involved in the reaction, for example, dimethylformamide, tetrahydrofuran, dimethylsulfoxide, and dichloromethane.
- the reaction can be carried out at a temperature ranging from 0 ° C to 140 ° C.
- a halogenated aniline that can be synthesized by a known method or a commercially available halogenated aniline and a ketoester are imidized using a suitable solvent (for example, benzene, toluene, or xylene) in the presence or absence of an acid catalyst.
- a suitable solvent for example, benzene, toluene, or xylene
- the compound of the formula (II) can be produced by cyclization in a high boiling point solvent such as diphenyl ether or cyclization in a solvent such as toluene or xylene using an acid catalyst.
- Acid catalysts used for imidization and cyclization include trifluoroboron etherate, tosylic acid, polyphosphoric acid and the like. The imidization and the cyclization may be performed in two steps by changing the solvent as necessary, or may be performed in the same solvent.
- any pyrethroid insecticide known in the art can be used.
- pyrethroid insecticides that can be used in the present invention include pyrethrin (Pyrethrin), allethrin (Allethrin), pralethodine (Prallethrin), propanolethrin (Proparthrin), furametrin (Furamethrin), and pyrethrin.
- Trines (Pyresmethrin), Resmethrin (Resmethrin), Cismethrin (Cismethrin), Bioresmethrin (Bioresmethrin), Cadethrin (Kadethrin), Imiprothrin (Imiprothrin), Phenothrin, Phenothrin (Perme thrin), transformer unloading less Li emissions (Transf luthrin), Fen off Norre Trinh (Fenfruth rin), Tefunoreto Li emissions (Tefluthrin), Bifento Li emissions (Bif enthrin), Fen Purono ⁇ 0 Bok Li emissions (Fenpropathrin), Shifueno Cytrinothrin, Cyhalothrin, Cypermethrin, Cyfluthrin rin), denoletamethrin (Deltamethrin), tralomethrin (Traloraethr
- the pyrethroid insecticide comprises fuoremetrine, It is selected from the group consisting of lumetrine and cyfluthrin.
- Other ingredients
- an effective amount of at least one compound selected from the group consisting of one or more compounds of the formula (I) and pyrethroid insecticides is used as a pharmaceutical additive.
- a parenteral administration such as oral administration, injection (intramuscular, subcutaneous, intravenous, intraperitoneal) as a parasite control composition according to the present invention; immersion, spray, bathing, washing, pouring Transdermal administrations such as -on) and spotting-on and dusting; can be administered by nasal administration.
- the mixed composition according to the present invention can also be administered by molded articles using strips, plates, bands, collars, ear marks, limbs, bands, marking devices and the like.
- the mixed composition for controlling parasites according to the present invention When the mixed composition for controlling parasites according to the present invention is actually used, a composition consisting only of the above-mentioned active ingredient may be used as it is. Can be prepared and used. Therefore, upon administration, the mixed composition for controlling parasites according to the present invention can be made into a formulation in any dosage form suitable for the administration route.
- Optional dosage forms include solid preparations such as powders, granules, wettable powders, pellets, tablets, pills, capsules, and molded products containing the active compound; liquids for injection, liquids for oral administration, Liquid preparations for use on the skin or in the body cavity; solution preparations such as pore-on and spot-on preparations, flowables, emulsions; semisolid preparations such as ointments, gels and the like.
- the solid preparation can be used mainly for oral administration, or diluted with water or the like, for transdermal administration, or for environmental treatment.
- Solid preparations can be prepared by mixing the active compound with appropriate excipients, if necessary with the aid of excipients and converting into the desired form.
- Suitable excipients include, for example, inorganic substances such as carbonates, bicarbonates, phosphates, aluminum oxide, silica (silicon dioxide), kaolin, clay, and sugar, cellulose, pulverized.
- organic substances such as grains and starch.
- Injectable solutions can be administered intravenously, intramuscularly, or subcutaneously.
- Liquid for injection The compound can be prepared by dissolving the active compound in a suitable solvent and, if necessary, adding additives such as a solubilizer, an acid, a base, a buffering salt, an antioxidant, an antifoaming agent, and a protective agent.
- Suitable solvents include water, ethanol, butanol, 2-propanol, benzyl alcohol, glycerin, propylene glycol, polyethylene glycol, N-methylpyrrolidone and mixtures thereof, physiologically acceptable vegetable oils, And synthetic oils suitable for injection.
- Solubilizers include polyvinylpyrrolidone, polyoxyethylene peryl ether, sodium dioctylsulfosuccinate, polyoxyethylated castor oil, and polyoxyethylated No.
- Protecting agents include benzyl alcohol, trichlorobutanol, p-hydroxybenzoate, and n-butanol.
- Examples of the defoaming agent include emulsion type silicone.
- Oral solutions can be administered directly or diluted. It can be prepared in the same manner as for injection.
- Flowables, emulsions and the like can be administered directly or diluted transdermally or by environmental treatment.
- Solutions for use on the skin can be administered by dripping, spreading, rubbing, spraying, spraying, or applying by dipping (immersion, bathing or washing). These solutions can be prepared in the same manner as injectable solutions.
- Pour-on and spot-on agents are intended to apply or spray to a limited area of the skin, thereby immersing the active compound in the skin and causing it to act systemically.
- Drops and drops may be prepared by suspending or emulsifying the active ingredient in a suitable skin compatible solvent or solvent mixture. If necessary, auxiliary substances such as surfactants, coloring agents, absorption enhancers, antioxidants, light stabilizers and adhesives may be added.
- Suitable solvents include water, alcohol, glycol, 2-propanol, isopropanol, polyethylene glycol, polypropylene glycol, dipropylene glycol, hexylene glycol, glycerin, benzyl alcohol, phenylethanol, and phenoxy.
- Absorption enhancers include dimethyl sulfoxide (DMSO), isopropyl myristate, dipropylene glycol pelargonate, silicone oils, aliphatic esters, triglycerides, and fatty alcohols.
- Antioxidants include sulfites, metabisulfites, ascorbic acid, butylhydroxytoluene, butydroxyacetic acid, and tocopherol.
- Emulsions can be administered orally, dermally or by injection.
- the emulsion is prepared by dissolving the active ingredient in a hydrophobic phase or a hydrophilic phase, and dissolving the active ingredient with a suitable emulsifier.
- a colorant, an absorption enhancer, a protective agent, an antioxidant, a light-shielding agent and It can be prepared by homogenizing with other phase solvents together with auxiliaries such as viscous substances.
- hydrophobic phase examples include paraffin oil, silicone oil, sesame oil, almond oil, castor oil, olive oil, synthetic triglyceride, ethyl stearate, di-n-butyryl adibinate, hexyl laurate, and pelargonic acid.
- Hydrophilic phases include water, propylene glycol, glycerin, and sorbitol.
- emulsifier examples include polyoxyethylated castor oil, polyoxyethylated sorbitan monooleate, sorbitan monostearate, glyceryl monostearate, polyoxyethyl ethyl stearate, and alkylphenol polyglycoside.
- Non-ionic surfactants such as toluene ether; amphoteric surfactants such as disodium N-lauryl-iminodipropionate and lecithin; sodium radium sulfate, sodium disobutinorenaphthalenesolephonate, n-dodecy Anionic surfactants such as calcium norebenzenesnolenate, sodium salt of naphthalenesulfonic acid formalin condensate, fatty alcohol sulfate ether, monoethanolamine salt of monodialkylpolyglycol orthophosphate and the like; and chloride And cationic surfactants such as cetyl trimethylammonium.
- adjuvants include carboxymethylcellulose, methylcellulose, polyatalylate, anoreginate, gelatin, gum arabic, polyvinylpyrrolidone, polyvinyl alcohol, methylbutyl ether, a copolymer of maleic anhydride, polyethylene dalicol, and wax. , And colloidal silica.
- Semi-solid preparations can be administered by spreading or spreading on the skin or by introducing them into body cavities.
- Gels can be prepared by adding to the solution prepared above for injectable solutions a thickener sufficient to produce a clear, ointment-like viscous substance.
- the above-mentioned other components may be used in combination of two or more selected from within each group and between each group.
- formulations can also be prepared by mixing with other insecticides, such as organophosphorus pesticides, carbamate pesticides, and pyrethroid pesticides.
- insecticides such as organophosphorus pesticides, carbamate pesticides, and pyrethroid pesticides.
- these preparations can be prepared by mixing with a synergist such as piperonyl butoxide. Furthermore, these preparations can also be prepared by mixing with other ectoparasite-controlling insecticides, endoparasite-controlling agents such as anthelmintics, or antibacterial agents.
- the compound of the formula (I) or a salt thereof and at least one compound selected from pyrethroid insecticides are combined in the total amount (active ingredient amount). It is sufficient that the mixture is mixed so as to have a ratio of 0.1 to 0.9 parts by weight, preferably 1 to 50 parts by weight, in 100 parts by weight of the parasite control mixed composition.
- the amount of the active ingredient can be appropriately selected in consideration of the formulation, administration method, use environment, and other conditions of the parasite control mixed composition.
- the parasite control When the mixed composition for removal is in the form of a wettable powder, the amount of the active ingredient is 0.1 to 99% by weight. /. Preferably 0.5 to 50% by weight, and 0.1 to 99% by weight, preferably 0.1 to 30% by weight when the parasite control mixed composition is in the form of a powder. is there.
- the combination ratio of the compound of the formula (I) or a salt thereof to at least one compound selected from pyrethroid insecticides is 1:99 to 9-9. The ratio is in the range of 9: 1, preferably in the range of 10:90 to 90:10.
- the mixed composition for controlling ectoparasites according to the present invention may be used directly as it is, but if necessary, diluted with a diluent such as water to give the target mammals and birds an oral solution. It can be administered or parenterally.
- a diluent such as water
- the mixed composition for controlling ectoparasites according to the present invention exhibited excellent control activity against ectoparasites that parasitized constant-temperature animals. Therefore, the mixed composition for controlling external parasites may be used for humans, magpies, pomas, pigs, higgies, goats, camels, mouths, dogs, cats, egrets, monkeys, guinea pigs, hamsters, etc. It can be used for controlling parasites that are parasitic on mammals and birds such as chickens, ducks, geese and turkeys.
- the ectoparasites include, for example, lice (Anoplura) such as the lice (Haematopinus spp.); , For example, chicken louse
- the mixed composition for controlling ectoparasites according to the present invention can also be used for controlling such parasitic parasites in the body.
- control parasites here means to control ectoparasites that have infested mammals and birds, and to prevent ectoparasites from infesting mammals and birds. Included.
- ectoparasites of mammals and birds comprising a step of administering an effective amount of the mixed composition for controlling parasites according to the present invention to mammals and birds of interest.
- a method for controlling pests is provided.
- target mammals and birds are mammals and birds that require ectoparasite control, that is, mammals that are or are likely to have ectoparasites. And birds.
- the amount of the mixed composition for controlling parasites according to the present invention depends on the environment in which it is used, the state of the target mammal and bird, the mixing ratio of the active ingredients, the formulation, the administration method, the type of parasite to be controlled, and the like. Can be changed as appropriate.
- the amount of the mixed composition for controlling parasites is usually such that the amount of the active ingredient per 1 kg of body weight of the target mammal and bird is 0.0001 to 10 g, preferably 0.010 to 1 g. ⁇ : An amount such that L g is obtained.
- the mixed composition for controlling parasites according to the present invention is usually prepared in advance and formulated as described above, and the compound of the formula (I), which is an active ingredient in the composition, is usually used. Or a salt thereof and at least one compound selected from pyrethroid insecticides Each of the compounds may be prepared in the form of a formulation containing the compound alone, and when used, these may be mixed in situ.
- the compound of formula (I) or a salt thereof is provided as a first composition comprising the compound as an active ingredient, and a pyrethroid insecticide is provided.
- At least one compound selected from is provided as a second composition comprising it as an active ingredient.
- the first composition and the second composition may be in any dosage form by using an appropriate carrier or auxiliary agent in combination, as in the case of the above-mentioned mixed composition for controlling parasites. it can.
- the combination may be provided in the form of a drug set.
- the combination for producing a mixed composition for controlling ectoparasites of mammals and birds can also be referred to as a parasiticide.
- a method for controlling ectoparasites of mammals and birds comprising:
- At least one compound selected from pyrethroid insecticides is administered simultaneously or separately to a target mammal and bird.
- administration comprises administering to the mammal and bird intended for the compound of formula (I) or a salt thereof and at least one compound selected from pyrethroid insecticides. Mixing prior to administration and administering the mixture is also included.
- Administration includes applying the compound of formula (I) or a salt thereof prior to the other component without premixing them, and adding the compound of formula (I) or a salt thereof to the other component. The application after the component is included.
- ectoparasites of mammals and birds Control method
- Example 1 2-ethyl-3-methyl-4-cyclopropanecarboninoleoxy-6,7-difluoroquinoline (compound 1) and 2-ethyl-3-methyl-14-cyclopropanecarbonyloxy 5,6 Difluoroquinoline (Compound 2)
- reaction solution was poured into water, extracted with ethyl acetate, and the obtained ethyl acetate layer was washed with a saturated aqueous solution of sodium hydrogen carbonate and a saturated saline solution.
- reaction solution was poured into water, extracted with ethyl acetate, and the obtained ethyl acetate layer was washed with saturated aqueous sodium hydrogen carbonate solution and saturated saline, dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure. I left.
- Raw material 1 (mixture of 2,3-dimethyl-4-hydroxy-6,7-difluoroquinoline and 2,2-dimethyl-4-hydroxy-5, -6-difluoroquinoline Three
- the reaction solution is poured into water, extracted with ethyl acetate, and the obtained ethyl acetate layer is washed with a saturated aqueous sodium hydrogen carbonate solution and a saturated saline solution, dried over anhydrous sodium sulfate, and then the solvent is distilled off under reduced pressure. did.
- the obtained crude product was purified with Kogel C-200 (200 ml; elution solvent n— ethyl hexyl monoacetate (10: 1)) to give 2,3-dimethinole 4-acetinoleoxy-16,7 —262.5 mg of quinoline (compound 17) of diphnoleo mouth was obtained.
- Table 3 shows the 1 H-NMR data.
- the obtained intermediate was refluxed in diphenyl ether for 30 minutes, and after standing to cool, the precipitate was collected by filtration under reduced pressure, and 2-ethyl-3-methyl-4-hydroxy-6-fluoro-17 monochloroquinoline, and 82 Omg of a mixture of 2-ethyl-3-methyl-4-hydroxy-5-chloro-6-fluoroquinoline was obtained.
- reaction solution was poured into water, extracted with ethyl acetate, and the obtained ethyl acetate layer was washed with a saturated aqueous sodium hydrogen carbonate solution and saturated saline, dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure. did.
- Example 7 2-Ethyl-3-methyl-14-cyclopropane force ponyloxy-16-fluoro-7-chloro mouth quinoline (compound 20), and 2-ethyl-3-methinolee 4-one-cycle propane canoleboninoleoxy-5 —Chloro-61 quinole quinoline (compound 21)
- the reaction solution was poured into water and extracted with ethyl acetate.
- the obtained ethyl acetate layer was washed with saturated aqueous sodium hydrogen carbonate solution and saturated saline, dried over anhydrous sodium sulfate, and then the solvent was evaporated under reduced pressure. Distilled off.
- the crude product obtained was purified with Kogel C-200 (200 ml; elution solvent n-hexane monoethyl acetate (10: 1)) to give 2-ethyl-3-methyl-4-propanecarbonylpropanecarbonyl.
- the reaction solution was poured into water, extracted with ethyl acetate, and the obtained ethyl acetate layer was washed with a saturated aqueous sodium hydrogen carbonate solution and saturated saline, dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure. .
- the obtained crude product was purified with ⁇ ⁇ .
- Kogel C-200 200 ml; elution solvent n-hexane-ethyl acetate (10: 1)) to give 2-ethyl-3-methyl-4-isopropoxyl.
- the reaction solution is poured into water, extracted with ethyl acetate, and the obtained ethyl acetate layer is washed with a saturated aqueous sodium hydrogen carbonate solution and saturated saline, dried over anhydrous sodium sulfate, and then the solvent is distilled off under reduced pressure. did.
- the resulting crude product was purified with Kogel C-200 (100 ml; elution solvent n— ethyl hexyl monoacetate (10: 1)) to give 2,3-dimethyl-4-six-propane-potassium propionyloxy.
- Example 13 3 2,3-Dimethyl-1- (3-transchloroacryloyloxy) -1,5,6-difluoroquinoline (Compound 53) and 2,3-Dimethyl4-1 (3-cischloroacyl) Liloyloxy) — 5, 6—Difluoroquinoline
- the reaction solution was poured into water, extracted with ethyl acetate, and the obtained ethyl acetate layer was washed with a saturated aqueous sodium hydrogen carbonate solution and saturated saline, dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure. .
- the obtained crude product was purified with ⁇ Kogel C-200 (100 ml; elution solvent n-hexane-ethyl acetate (10: 1)) to give 2,3-dimethyl-41- (3-transchloroacetate).
- the reaction solution was poured into water, extracted with ethyl acetate, and the obtained ethyl acetate layer was washed with a saturated aqueous solution of sodium hydrogen carbonate and saturated saline, dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure. I left.
- the obtained crude product was purified with a silica gel packed column (Varian) (20 g; elution solvent n-hexane-ethyl acetate (40: 1) to (20: 1)) to give a 2,3-dimethinolate.
- Example 17 2-Ethyl-3-methyl-4-1-methanthio-1-norecarbonyloxy-1,5, -6-difluoroquinoline (Compound 39) Under argon substitution and in the presence of dimethylaminopyridine, 30 mg of 2-ethinole 3-methylinole 4-hydroxy-5,6-diphnoleoquinoline (raw material 1) obtained by the method of Experimental Example 3 was suspended in dichloromethane. After adding 16 mg of triethylamine and stirring at room temperature for 30 minutes, 16 mg of methylchlorothioformate (raw material 2) was added and stirred for 1 minute.
- Compound 2 1.0 weight. /. Fullmethrin 1.0% by weight
- Light liquid paraffin 9 8 direct dose c
- Formulation example 7 Liquid for transdermal administration (drop)
- Silicone oil (Product name: Shin-Etsu Silicone, Shin-Etsu Chemical Co., Ltd.)
- Test example 1 Control effect of mites (Dermanyssus gal linae)
- the tip of the Pasteur pipe was sealed with parafilm, and an acetone solution of a sample diluted to a predetermined concentration was poured from above the pipe. After one minute, remove the parafilm at the tip, drain the drug solution, air-dry the pipette, insert absorbent cotton into the upper end of the pipette, 03012003
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Environmental Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR0314987-0A BR0314987A (pt) | 2002-10-11 | 2003-09-19 | Composição em mistura para o controle de ectoparasitas de manìferos e aves, método para o contrloe de um ectoparasita de mamìferos e aves, combinação, e, uso da mesma |
AU2003266542A AU2003266542A1 (en) | 2002-10-11 | 2003-09-19 | Mixed compositions for controlling parasitic insects |
EP03807972A EP1559321A1 (en) | 2002-10-11 | 2003-09-19 | Mixed compositions for controlling parasitic insects |
JP2004542812A JPWO2004032629A1 (ja) | 2002-10-11 | 2003-09-19 | 寄生虫防除用混合組成物 |
CA002501767A CA2501767A1 (en) | 2002-10-11 | 2003-09-19 | Mixture compositions for controlling ectoparasites |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002299653 | 2002-10-11 | ||
JP2002-299653 | 2002-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004032629A1 true WO2004032629A1 (ja) | 2004-04-22 |
Family
ID=32089345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/012003 WO2004032629A1 (ja) | 2002-10-11 | 2003-09-19 | 寄生虫防除用混合組成物 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1559321A1 (ja) |
JP (1) | JPWO2004032629A1 (ja) |
KR (1) | KR20050067177A (ja) |
CN (1) | CN1688193A (ja) |
AR (1) | AR041574A1 (ja) |
AU (1) | AU2003266542A1 (ja) |
BR (1) | BR0314987A (ja) |
CA (1) | CA2501767A1 (ja) |
WO (1) | WO2004032629A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010053129A (ja) * | 2008-07-31 | 2010-03-11 | Meiji Seika Kaisha Ltd | 有害生物防除用組成物 |
WO2018169045A1 (ja) | 2017-03-17 | 2018-09-20 | Meiji Seikaファルマ株式会社 | 中気門亜目ダニ類の防除剤 |
WO2020054835A1 (ja) * | 2018-09-14 | 2020-03-19 | Meiji Seikaファルマ株式会社 | 中気門亜目ダニ類の防除用組成物 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103214461B (zh) * | 2013-04-22 | 2015-05-27 | 山东省联合农药工业有限公司 | 一种喹啉衍生物及其用途 |
JP6699002B2 (ja) * | 2015-11-11 | 2020-05-27 | 国立大学法人高知大学 | スズメバチ科ハチ忌避剤 |
CN108689928B (zh) * | 2018-07-19 | 2020-05-26 | 山东省联合农药工业有限公司 | 一种喹啉类衍生物及其制备方法与用途 |
CN111205223B (zh) * | 2020-03-03 | 2021-06-22 | 山东省联合农药工业有限公司 | 喹啉类衍生物及其制备方法与用途 |
CN114957116A (zh) * | 2022-07-01 | 2022-08-30 | 浙江工业大学 | 2,3-二甲基-8-氟喹啉-4-酯类化合物及其制备方法和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0407192A2 (en) * | 1989-07-07 | 1991-01-09 | Meiji Seika Kabushiki Kaisha | 4-Acyloxyquinoline derivatives and insecticidal or acaricidal compositions containing same |
JPH0341004A (ja) * | 1989-07-06 | 1991-02-21 | Meiji Seika Kaisha Ltd | 殺虫、殺ダニ剤 |
US5194617A (en) * | 1988-12-17 | 1993-03-16 | Meiji Seika Kaisha, Ltd. | 2,3-disubstituted-4-hydroxyquinoline derivatives |
WO2001036408A1 (en) * | 1999-11-15 | 2001-05-25 | New Pharma Research Sweden Ab | Compounds with antibacterial and antiparasitic properties |
WO2001090075A1 (fr) * | 2000-05-25 | 2001-11-29 | Ishihara Sangyo Kaisha, Ltd. | Compositions combattant les ectoparasites des animaux |
WO2002083644A1 (fr) * | 2001-04-12 | 2002-10-24 | Meiji Seika Kaisha, Ltd. | Derives de quinoline halogenes et agents d'elimination des ectoparasites |
-
2003
- 2003-09-19 JP JP2004542812A patent/JPWO2004032629A1/ja active Pending
- 2003-09-19 EP EP03807972A patent/EP1559321A1/en not_active Withdrawn
- 2003-09-19 KR KR1020057006185A patent/KR20050067177A/ko not_active Application Discontinuation
- 2003-09-19 CA CA002501767A patent/CA2501767A1/en not_active Abandoned
- 2003-09-19 WO PCT/JP2003/012003 patent/WO2004032629A1/ja not_active Application Discontinuation
- 2003-09-19 CN CNA038240319A patent/CN1688193A/zh active Pending
- 2003-09-19 AU AU2003266542A patent/AU2003266542A1/en not_active Abandoned
- 2003-09-19 BR BR0314987-0A patent/BR0314987A/pt not_active Application Discontinuation
- 2003-10-09 AR ARP030103686A patent/AR041574A1/es unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194617A (en) * | 1988-12-17 | 1993-03-16 | Meiji Seika Kaisha, Ltd. | 2,3-disubstituted-4-hydroxyquinoline derivatives |
JPH0341004A (ja) * | 1989-07-06 | 1991-02-21 | Meiji Seika Kaisha Ltd | 殺虫、殺ダニ剤 |
EP0407192A2 (en) * | 1989-07-07 | 1991-01-09 | Meiji Seika Kabushiki Kaisha | 4-Acyloxyquinoline derivatives and insecticidal or acaricidal compositions containing same |
WO2001036408A1 (en) * | 1999-11-15 | 2001-05-25 | New Pharma Research Sweden Ab | Compounds with antibacterial and antiparasitic properties |
WO2001090075A1 (fr) * | 2000-05-25 | 2001-11-29 | Ishihara Sangyo Kaisha, Ltd. | Compositions combattant les ectoparasites des animaux |
WO2002083644A1 (fr) * | 2001-04-12 | 2002-10-24 | Meiji Seika Kaisha, Ltd. | Derives de quinoline halogenes et agents d'elimination des ectoparasites |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010053129A (ja) * | 2008-07-31 | 2010-03-11 | Meiji Seika Kaisha Ltd | 有害生物防除用組成物 |
WO2018169045A1 (ja) | 2017-03-17 | 2018-09-20 | Meiji Seikaファルマ株式会社 | 中気門亜目ダニ類の防除剤 |
KR20190137782A (ko) | 2017-03-17 | 2019-12-11 | 메이지 세이카 파루마 가부시키가이샤 | 중기문아목 진드기류의 방제제 |
WO2020054835A1 (ja) * | 2018-09-14 | 2020-03-19 | Meiji Seikaファルマ株式会社 | 中気門亜目ダニ類の防除用組成物 |
JP7389750B2 (ja) | 2018-09-14 | 2023-11-30 | Meiji Seikaファルマ株式会社 | 中気門亜目ダニ類の防除用組成物 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004032629A1 (ja) | 2006-02-02 |
CA2501767A1 (en) | 2004-04-22 |
CN1688193A (zh) | 2005-10-26 |
AR041574A1 (es) | 2005-05-18 |
BR0314987A (pt) | 2005-08-09 |
KR20050067177A (ko) | 2005-06-30 |
EP1559321A1 (en) | 2005-08-03 |
AU2003266542A1 (en) | 2004-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016204502B2 (en) | Topical compositions comprising fipronil and permethrin and methods of use | |
BRPI0815227B1 (pt) | uso de isoxazolina | |
JPH03115266A (ja) | N―フェニルピラゾール誘導体 | |
JP6041359B2 (ja) | アミドピリジルエーテル化合物及び組成物並びに寄生虫に対するそれらの使用 | |
EP0303933A2 (de) | Neue Avermectin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung | |
WO2004032629A1 (ja) | 寄生虫防除用混合組成物 | |
EP2222164A1 (en) | Dihydroquinolinones as ectoparasiticides | |
JPH0380138B2 (ja) | ||
EP1386914B1 (en) | Halogenated quinoline derivatives and ectoparasite controllers | |
CN103214461A (zh) | 一种喹啉衍生物及其用途 | |
JPS62230787A (ja) | マクロライド抗生物質 | |
US20040077602A1 (en) | Mixture composition for controlling ectoparasites | |
KR960006390B1 (ko) | 마크롤리드 화합물 | |
DD298926A5 (de) | Pestizide | |
CN110742068A (zh) | 百秋李醇的用途及杀螨剂 | |
CA1110633A (en) | Benzimidazol carbamate active against gastroenteric and lung parasites | |
JP2976038B2 (ja) | 新規アミジン誘導体、及びこれを含有する殺虫、殺ダニ剤 | |
JPS6019751B2 (ja) | ベンジリデンケトン系化合物、その製造法および該化合物からなる殺菌剤 | |
JPS632988A (ja) | 1,3−ジチオ−ル−2−イリデン スルホニル酢酸誘導体 | |
KR960006389B1 (ko) | 마크롤리드 화합물 | |
US4201789A (en) | Cyclopropanecarboxylic acid naphthylmethyl ester | |
JP2923568B2 (ja) | ピレスロイド系化合物の安定化方法 | |
DE19705718A1 (de) | Neue Oxirancarbonsäuren zur Behandlung des Diabetes Typ 2 und anderer insulinresistenter Zustände | |
WO2003086077A1 (fr) | Compositions anti-tiques ou anti-puces pour les animaux | |
JPS6328919B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003266542 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 539236 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057006185 Country of ref document: KR Ref document number: 2501767 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038240319 Country of ref document: CN Ref document number: 2004542812 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200500574 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003807972 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057006185 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003807972 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003807972 Country of ref document: EP |